Janney Montgomery Scott LLC Has $13.68 Million Position in Sanofi $SNY

Posted by Stanley Muller on Jul 2nd, 2026

Janney Montgomery Scott LLC lowered its holdings in Sanofi (NASDAQ:SNY – Free Report) by 36.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 283,918 shares of the company’s stock after selling 159,575 shares during the period. Janney Montgomery Scott LLC’s holdings in Sanofi were worth $13,679,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of SNY. Advisory Services Network LLC lifted its stake in Sanofi by 1.4% in the 3rd quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock worth $743,000 after acquiring an additional 210 shares in the last quarter. Savant Capital LLC lifted its position in shares of Sanofi by 2.7% in the fourth quarter. Savant Capital LLC now owns 8,623 shares of the company’s stock worth $418,000 after purchasing an additional 225 shares in the last quarter. Wesbanco Bank Inc. boosted its holdings in shares of Sanofi by 4.9% during the fourth quarter. Wesbanco Bank Inc. now owns 4,927 shares of the company’s stock worth $239,000 after purchasing an additional 230 shares during the period. IFG Advisory LLC boosted its holdings in shares of Sanofi by 2.7% during the fourth quarter. IFG Advisory LLC now owns 9,213 shares of the company’s stock worth $446,000 after purchasing an additional 244 shares during the period. Finally, GAMMA Investing LLC grew its position in Sanofi by 5.5% during the fourth quarter. GAMMA Investing LLC now owns 5,058 shares of the company’s stock valued at $245,000 after purchasing an additional 264 shares in the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Sanofi Price Performance

Shares of SNY opened at $41.63 on Thursday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.22 and a current ratio of 1.01. The firm has a market cap of $100.93 billion, a PE ratio of 11.63, a PEG ratio of 1.05 and a beta of 0.35. The firm’s 50 day moving average price is $43.84 and its 200 day moving average price is $45.90. Sanofi has a twelve month low of $40.89 and a twelve month high of $52.68.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which was paid on Wednesday, June 3rd. Stockholders of record on Monday, May 4th were issued a dividend of $2.4225 per share. The ex-dividend date was Monday, May 4th. This represents a dividend yield of 559.0%. This is an increase from Sanofi’s previous annual dividend of $2.04. Sanofi’s payout ratio is 49.16%.

Analysts Set New Price Targets

SNY has been the subject of a number of research analyst reports. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, March 19th. Argus upgraded shares of Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a research note on Monday, April 13th. Weiss Ratings raised Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Finally, BNP Paribas Exane downgraded Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 target price on the stock. in a research note on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $51.00.

Check Out Our Latest Research Report on Sanofi

Sanofi Profile

(Free Report)

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.